Sökning: onr:"swepub:oai:gup.ub.gu.se/331839" > Haematopoietic stem...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 10291naa a2200961 4500 | |
001 | oai:gup.ub.gu.se/331839 | |
003 | SwePub | |
008 | 240528s2023 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-108563 | |
009 | oai:prod.swepub.kib.ki.se:153743742 | |
009 | oai:DiVA.org:liu-198393 | |
009 | oai:lup.lub.lu.se:48351675-aed2-43af-ac24-7553fcf3ae26 | |
009 | oai:DiVA.org:uu-528598 | |
024 | 7 | a https://gup.ub.gu.se/publication/3318392 URI |
024 | 7 | a https://doi.org/10.1136/jnnp-2023-3318642 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1085632 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1537437422 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1983932 URI |
024 | 7 | a https://lup.lub.lu.se/record/48351675-aed2-43af-ac24-7553fcf3ae262 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5285982 URI |
040 | a (SwePub)gud (SwePub)orud (SwePub)kid (SwePub)liud (SwePub)lud (SwePub)uu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Silfverberg, Thomasu Uppsala universitet,Uppsala University,Center for Clinical Research Dalarna,Centrum för klinisk forskning Dalarna,Hematologi4 aut0 (Swepub:uu)thosi392 |
245 | 1 0 | a Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study |
264 | 1 | b BMJ Publishing Group Ltd,c 2023 |
500 | a Funding Agencies|This study was presented as an abstract and oral presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting, Paris, 23-26 April 2023. | |
520 | a BackgroundA growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet been integrated into most national clinical guidelines. The objective of this study was to assess efficacy and safety when aHSCT is implemented in routine healthcare.MethodsWe assessed 231 patients and the final analysis included 174 RRMS patients who were treated with aHSCT in Sweden before 1 January 2020. Efficacy was evaluated by performing a retrospective analysis of prospectively collected data from the Swedish MS registry. Procedure-related safety was assessed by analysing data from electronic patient records covering a period of 100 days following aHSCT.ResultsWith a median follow-up time of 5.5 (IQR: 3.4-7.5) years, the Kaplan-Meier estimate for no evidence of disease activity was 73% (95% CI 66% to 81%) at 5 years and 65% (95% CI 57% to 75%) at 10 years. Out of the 149 patients with baseline disability, 80 (54%) improved, 55 (37%) were stable and 14 (9%) deteriorated. The mean number of adverse events per patient was 1.7 (& PLUSMN;SD: 1.5) for grade 3 events and 0.06 (& PLUSMN;SD: 0.3) for grade 4 events. Febrile neutropenia was the most common adverse event, affecting 68% of patients. There was no treatment-related mortality.ConclusionsTreatment with aHSCT for RRMS is associated with freedom from disease activity in a majority of patients, with acceptable adverse events. This procedure should be considered a standard of care for patients with highly active RRMS. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinsk bioteknologix Medicinsk bioteknologi0 (SwePub)304012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Medical Biotechnologyx Medical Biotechnology0 (SwePub)304012 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
653 | a multiple sclerosis | |
653 | a haematology | |
653 | a clinical neurology | |
653 | a disease-modifying therapy | |
653 | a alemtuzumab | |
653 | a ms | |
653 | a Neurosciences & Neurology | |
653 | a Psychiatry | |
653 | a Surgery | |
653 | a CLINICAL NEUROLOGY | |
653 | a CLINICAL NEUROLOGY | |
653 | a HAEMATOLOGY | |
653 | a MULTIPLE SCLEROSIS | |
700 | 1 | a Zjukovskaja, Christinau Uppsala universitet,Uppsala University,Experimentell neurologi4 aut0 (Swepub:uu)chrzh593 |
700 | 1 | a Ljungman, P.u Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden.;Karolinska Univ, Karolinska Comprehens Canc Ctr, Dept Cellular Therapy & Allogene Stem Cell Transpl, Hosp Huddinge, Stockholm, Sweden.,Karolinska University Hospital4 aut |
700 | 1 | a Nahimi, Adjmalu Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Restorative Parkinson Unit,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital,Skane Univ Hosp, Dept Neurol Rehabil Med Memory Disorders & Geriatr, Lund, Sweden.4 aut0 (Swepub:lu)ad7381na |
700 | 1 | a Ahlstrand, Erik,d 1974-u Örebro University,Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Medicine,Örebro Univ, Fac Med & Hlth, Dept Med, Örebro, Sweden.4 aut0 (Swepub:oru)ead |
700 | 1 | a Dreimane, Artau Department of Hematology, Linköping University Hospital, Linköping, Sweden,Region Östergötland, Hematologiska kliniken US,Linköping Univ Hosp, Dept Hematol, Linköping, Sweden.4 aut0 (Swepub:liu)artdr13 |
700 | 1 | a Einarsdottir, Sigrunu University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Hematology and Coagulation, Sahlgrenska Sjukhuset, Gothenburg, Sweden,Univ Gothenburg, Inst Med, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Hematol & Coagulat, Gothenburg, Sweden.,Sahlgrenska University Hospital4 aut0 (Swepub:gu)xeinsi |
700 | 1 | a Fagius, Janu Uppsala universitet,Uppsala University,Neurologi4 aut0 (Swepub:uu)janfagiu |
700 | 1 | a Iacobaeus, E.u Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.,Karolinska University Hospital4 aut |
700 | 1 | a Hägglund, Hansu Uppsala universitet,Uppsala University,Karolinska University Hospital,Hematologi,Karolinska Univ, Karolinska Comprehens Canc Ctr, Dept Cellular Therapy & Allogene Stem Cell Transpl, Hosp Huddinge, Stockholm, Sweden.4 aut0 (Swepub:uu)hanha689 |
700 | 1 | a Lange, Niclas,d 1990-u Örebro University,Örebro Univ, Fac Med & Hlth, Dept Med, Örebro, Sweden.4 aut0 (Swepub:oru)nle |
700 | 1 | a Lenhoff, Stigu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital,Skane Univ Hosp Lund, Dept Hematol Oncol & Radiophys, Lund, Sweden.4 aut0 (Swepub:lu)med-slf |
700 | 1 | a Lycke, Jan,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden,Sahlgrens Acad, Dept Clin Neurosci, Inst Neurosci & Physiol, Gothenburg, Sweden.4 aut0 (Swepub:gu)xlycja |
700 | 1 | a Mellergård, Johanu Linköping University,Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping Univ, Dept Neurol, Linköping, Sweden.;Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)johme15 |
700 | 1 | a Piehl, F.u Karolinska Institute,Karolinska Institutet,Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.,Karolinska University Hospital4 aut |
700 | 1 | a Svenningsson, A.u Karolinska Institutet,Karolinska Inst, Dept Clin Sci, Institutionen Kliniska Vetenskaper, Danderyds Sjukhus, Stockholm, Sweden.;Karolinska Inst, Dept Neurol, Institutionen Kliniska Vetenskaper, Danderyds Sjukhus, Stockholm, Sweden.,Danderyd Hospital4 aut |
700 | 1 | a Tolf, Andreasu Uppsala universitet,Uppsala University,Experimentell neurologi4 aut0 (Swepub:uu)andto164 |
700 | 1 | a Cherif, Honaru Uppsala universitet,Uppsala University,Hematologi4 aut0 (Swepub:uu)honch489 |
700 | 1 | a Carlson, Kristinau Uppsala universitet,Uppsala University,Hematologi4 aut0 (Swepub:uu)krica965 |
700 | 1 | a Burman, Joachim,d 1974-u Uppsala universitet,Uppsala University,Experimentell neurologi4 aut0 (Swepub:uu)joabu293 |
710 | 2 | a Uppsala Universityb Center for Clinical Research Dalarna4 org |
773 | 0 | t Journal of Neurology Neurosurgery and Psychiatryd : BMJ Publishing Group Ltdx 0022-3050x 1468-330X |
856 | 4 | u https://doi.org/10.1136/jnnp-2023-331864y Fulltext |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1803862/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1136/jnnp-2023-331864x freey FULLTEXT |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1860705/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://gup.ub.gu.se/publication/331839 |
856 | 4 8 | u https://doi.org/10.1136/jnnp-2023-331864 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-108563 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153743742 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-198393 |
856 | 4 8 | u https://lup.lub.lu.se/record/48351675-aed2-43af-ac24-7553fcf3ae26 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528598 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy